In the fourth quarter of fiscal year 2026, Sun Pharma reported a consolidated profit after tax (PAT) of Rs 2,714 crore, marking a 26% increase compared to the same period last year. However, the company experienced a 19% sequential decline in PAT from Rs 3,369 crore in Q3 FY26. Revenue for the quarter fell by 6% sequentially from Rs 15,520 crore reported in the previous quarter. Despite these fluctuations, Sun Pharma's board approved a dividend of Rs 5 per share, indicating confidence in the company's financial stability amid market challenges. Sun Pharma Q4 Results: Profit after tax (PAT) fell 19% sequentially during the quarter under review from Rs 3,369 crore in Q3FY26, while revenue declined 6% from Rs 15,520 crore reported in the October-December quarter of FY26.